Stockscreener 앱 받기
91.98
0.54%
-0.50
시간 외 거래:
91.98
전일 마감가:
$92.48
열려 있는:
$92.24
하루 거래량:
819.55K
Relative Volume:
1.13
시가총액:
$5.85B
수익:
$136.86M
순이익/손실:
$-168.69M
주가수익비율:
-32.73
EPS:
-2.81
순현금흐름:
$-113.49M
1주 성능:
+4.17%
1개월 성능:
+41.20%
6개월 성능:
+55.42%
1년 성능:
+100.52%
1일 변동 폭
$90.48
$93.71
1주일 범위
$85.73
$93.71
52주 변동 폭
$43.57
$94.80
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
명칭
Rhythm Pharmaceuticals Inc
전화
857-264-4280
주소
222 BERKELEY STREET, BOSTON, MA
RYTM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
91.98 | 5.98B | 136.86M | -168.69M | -113.49M | -2.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-10 | 개시 | Goldman | Buy |
| 2025-07-07 | 개시 | Leerink Partners | Outperform |
| 2025-04-07 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-03-05 | 재개 | Stifel | Buy |
| 2025-01-02 | 개시 | Jefferies | Buy |
| 2024-12-20 | 개시 | Oppenheimer | Outperform |
| 2024-10-21 | 개시 | Guggenheim | Buy |
| 2024-09-18 | 개시 | H.C. Wainwright | Buy |
| 2024-09-17 | 개시 | JMP Securities | Mkt Outperform |
| 2024-05-08 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-08-01 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-01-18 | 재개 | Canaccord Genuity | Buy |
| 2022-08-08 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-08-05 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-06-17 | 재확인 | Needham | Buy |
| 2022-03-02 | 재개 | Stifel | Buy |
| 2022-02-17 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-14 | 재개 | Goldman | Neutral |
| 2021-08-04 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-08-04 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-30 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-01-08 | 개시 | Goldman | Sell |
| 2019-07-12 | 업그레이드 | Stifel | Hold → Buy |
| 2019-07-08 | 개시 | Canaccord Genuity | Buy |
| 2019-03-13 | 개시 | Ladenburg Thalmann | Buy |
| 2018-09-07 | 재개 | Morgan Stanley | Overweight |
| 2018-06-25 | 재확인 | Needham | Buy |
| 2018-06-15 | 재확인 | Needham | Buy |
| 2017-10-30 | 개시 | BofA/Merrill | Buy |
| 2017-10-30 | 개시 | Needham | Buy |
모두보기
Rhythm Pharmaceuticals Inc 주식(RYTM)의 최신 뉴스
Rhythm Pharmaceuticals prices $175M stock offering - MSN
Rhythm Pharmaceuticals Inc. Forms Bullish Flag — Upside AheadSmart Allocation Stock Pick Insights Gaining Interest - beatles.ru
Rhythm Pharmaceuticals: Unlocking Value as Key Lock-Up Expiry and Setmelanotide Regulatory Milestones Loom - AInvest
Rhythm Pharmaceuticals and the Impending Lock-Up Expiry: A Catalyst for Shareholder Value Realization - AInvest
Rhythm Pharmaceuticals: A Post-Lock-Up Opportunity with Strong Catalysts in Q3 2025 and Beyond - AInvest
Rhythm Pharmaceuticals Lock-Up Agreement Ends on August 9, 2025 - AInvest
Pediatric Obesity Market Expected to Experience Major Growth by 2034, According to DelveInsight | VIVUS LLC, Novartis, Rhythm Pharmaceuticals, Jack Yanovski - The Globe and Mail
12 Analysts Weigh In on Rhythm Pharmaceuticals: A Comprehensive Analysis of Ratings and Price Targets - AInvest
Rhythm Pharmaceuticals Exceeds Q2 Expectations, Maintains Buy Rating - AInvest
Leerink Partners Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Announces Target Price $102 - 富途牛牛
Strong Q2 Performance and Strategic Investments Drive Buy Rating for Rhythm Pharmaceuticals - TipRanks
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q2 2025 Earnings Call Transcript - Insider Monkey
Rhythm Pharmaceuticals stock price target raised to $100 from $80 at H.C. Wainwright - Investing.com Canada
HC Wainwright Raises PT to $100, Maintains Buy Rating on Rhythm Pharmaceuticals. - AInvest
Loss-Making Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Expected To Breakeven In The Medium-Term - Yahoo Finance
Rhythm Pharmaceuticals’ Earnings Call Highlights Growth and Challenges - TipRanks
Positive Outlook on Rhythm Pharmaceuticals: Strong Growth Potential and Strategic Advancements Support Buy Rating - TipRanks
Guggenheim Raises Rhythm Pharmaceuticals Buy Rating, PT to $120 - AInvest
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates - MSN
Citizens JMP raises Rhythm Pharmaceuticals stock price target to $135 on growth - Investing.com Canada
Rhythm Pharmaceuticals shares rise 3.30% premarket after reporting Q2 2025 earnings. - AInvest
Rhythm Pharmaceuticals Inc (RYTM) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Rhythm Pharmaceuticals Inc (RYTM) Q2 2025 Earnings Call Highligh - GuruFocus
Rhythm Pharmaceuticals Reports Strong Q2 2025 Growth - TipRanks
Rhythm Pharmaceuticals Q2 Revenue Surpasses Estimates, Up 67% YoY - AInvest
Rhythm Pharmaceuticals Achieves 29% QoQ Revenue Growth, Sets Sights on HO Regulatory Filings - AInvest
Rhythm Pharmaceuticals' Q2 2025: Navigating Key Contradictions in Trial Design, Stock Compensation, and Market Dynamics - AInvest
Needham Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $95 - 富途牛牛
Rhythm Pharmaceuticals stock price target raised to $110 from $85 at TD Cowen - Investing.com Canada
Rhythm Pharmaceuticals price target raised to $109 from $100 at Morgan Stanley - TipRanks
Rhythm Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Positive Outlook for Rhythm Pharmaceuticals: Strong Revenue Performance and Promising Future Catalysts Justify Buy Rating - TipRanks
Rhythm Pharmaceuticals Q2 2025 slides: Revenue jumps 29%, obesity drugs show promise - Investing.com Canada
Rhythm Pharmaceuticals Q2 revenue up 67% yr/yr, net loss widens - MarketScreener
Rhythm Pharmaceuticals Reports Q2 GAAP EPS of -$0.75, Revenue at $48.5 Million - AInvest
Rhythm Pharmaceuticals enrolls first patient in Part C of Phase 1 RM-718 trial - TipRanks
Rhythm Pharmaceuticals Q2 2025 Financial Results and Business Update - TradingView
Rhythm Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Update - GlobeNewswire
Rhythm Pharmaceuticals Q2 net product revenue $48.5mln, raises $189.2mln. - AInvest
How strong is Rhythm Pharmaceuticals Inc. company’s balance sheetDiscover top stock picks for aggressive growth - Jammu Links News
How does Rhythm Pharmaceuticals Inc. generate profit in a changing economyHigh-margin investment plays - Jammu Links News
What are the latest earnings results for Rhythm Pharmaceuticals Inc.Free Investment Timing Strategies - Jammu Links News
Is it the right time to buy Rhythm Pharmaceuticals Inc. stockAchieve breakthrough financial results today - Jammu Links News
Does Rhythm Pharmaceuticals Inc. stock perform well during market downturnsRapid wealth multiplication - Jammu Links News
Is Rhythm Pharmaceuticals Inc. stock overvalued or undervaluedRecord-breaking gains - Jammu Links News
How does Rhythm Pharmaceuticals Inc. compare to its industry peersGet exclusive access to expert stock recommendations - Jammu Links News
What are Rhythm Pharmaceuticals Inc. company’s key revenue driversMaximize your gains with professional insights - Jammu Links News
Why is Rhythm Pharmaceuticals Inc. stock attracting strong analyst attentionAchieve rapid financial growth with expert help - Jammu Links News
Should I hold or sell Rhythm Pharmaceuticals Inc. stock in 2025Uncover the best stocks for explosive growth - Jammu Links News
When is Rhythm Pharmaceuticals Inc. stock expected to show significant growthRapid wealth creation - Jammu Links News
Rhythm Pharmaceuticals shares rise 2.48% intraday after Ligand and Medtronic's $70 million investment in Orchestra BioMed. - AInvest
Rhythm Pharmaceuticals Inc (RYTM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):